Evidence map›Paper›PMID 42291797›Full record

ArticleClinical and translational radiation oncology2026

Impact of ataxia-telangiectasia mutated (ATM) loss on radiobiological and immune response to radium-223 in prostate cancer

Victoria L Dunne, Timothy C Wright, Aislinn Toner, Melissa LaBonte Wilson, Kienan I Savage, Joe M O'Sullivan, Kevin M Prise

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Victoria L DunneJohnston Cancer Research Centre, Queen's University Belfast, Northern Ireland, UK.
Timothy C WrightJohnston Cancer Research Centre, Queen's University Belfast, Northern Ireland, UK.
Aislinn TonerJohnston Cancer Research Centre, Queen's University Belfast, Northern Ireland, UK.
Melissa LaBonte WilsonJohnston Cancer Research Centre, Queen's University Belfast, Northern Ireland, UK.
Kienan I SavageJohnston Cancer Research Centre, Queen's University Belfast, Northern Ireland, UK.
Joe M O'SullivanJohnston Cancer Research Centre, Queen's University Belfast, Northern Ireland, UK.
Kevin M PriseJohnston Cancer Research Centre, Queen's University Belfast, Northern Ireland, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPersonalised medicine approaches are redefining the therapeutic landscape for men with metastatic castration-resistant prostate cancer (mCRPC). While poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated clinical benefit in patients with BRCA1/2 mutant tumours, the therapeutic efficacy of these inhibitors in Ataxia-telangiectasia mutated (ATM)-mutated prostate cancer patients remains modest, highlighting the need for alternative treatment strategies. This study aimed to elucidate the impact of ATM loss on radiobiological and immune responses to different radiation modalities in prostate cancer models.

methodsIsogenic CRISPR Cas-mediated ATM-deficient and wild-type (WT) cells were treated with X-rays or Radium-223 dichloride (

results

conclusionsThese findings demonstrate that ATM-deficiency enhances radiobiological response and amplifies immune activation to

Indexed as

ATM-depletioncGAS-STING pathwayDNA damageProstate cancerRadium-223X-rays

Identifiers

PMID42291797
PMCPMC13254887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.